RAF1 and neoplasm: The increasing knowledge has led to the discovery of various selective and immunomodulatory therapeutic approaches in an attempt to disrupt pathologically hyperactivated RAS-RAF-MEK-ERK signaling and tilt the balance of the tumor-TME-immune system crosstalk towards an anti-tumorigenic setting.